大型电子健康记录系统性红斑狼疮队列中耶氏肺孢子菌肺炎发生率及预防用药处方模式
在大型去标识化电子健康记录中,977例系统性红斑狼疮患者仅4例确诊耶氏肺孢子菌肺炎,其中2例合并获得性免疫缺陷综合征且均未接受预防。132例(14%)接受预防用药,磺胺类最常见(69%),117次磺胺暴露中记录22次可能不良事件。
要点
- 977例系统性红斑狼疮患者中仅4例确诊耶氏肺孢子菌肺炎,其中2例合并获得性免疫缺陷综合征且均未预防。
- 977例中132例(14%)接受预防用药;617例曾用免疫抑制剂者中128例(21%)接受预防。
- 磺胺类为最常见预防药物(69%),117次磺胺暴露中记录22次可能不良事件。
核心结论
- 耶氏肺孢子菌肺炎在系统性红斑狼疮患者中是罕见诊断,既往研究可能高估其患病率。
- 本队列中耶氏肺孢子菌肺炎预防用药比既往描述的更不常见。
- 用于预防的磺胺类药物相关不良事件相对罕见,发生率低于既往报告。
研究设计与样本
- 在大型去标识化电子健康记录中,使用既往验证过的算法识别可能的系统性红斑狼疮患者。
- 使用耶氏肺孢子菌肺炎的ICD-9或ICD-10-CM billing codes及关键词在该系统性红斑狼疮队列中识别可能的耶氏肺孢子菌肺炎病例。
- 通过关键词和审查药物列表评估所有系统性红斑狼疮患者的耶氏肺孢子菌肺炎预防处方。
- 通过病历审查确认系统性红斑狼疮、耶氏肺孢子菌肺炎和预防用药病例,并获取人口学、合并症和免疫抑制剂数据。
主要发现
- 977例系统性红斑狼疮患者中仅4例确诊耶氏肺孢子菌肺炎感染,其中2例合并获得性免疫缺陷综合征,且无一例接受预防。
- 977例系统性红斑狼疮患者中132例(14%)被处方耶氏肺孢子菌肺炎预防。
- 617例曾处方免疫抑制剂的系统性红斑狼疮患者中128例(21%)被处方耶氏肺孢子菌肺炎预防。
- 磺胺类药物是最常见的预防处方(69%),117次磺胺类药物预防暴露中记录22次可能不良事件。
- 较年轻、Black race、肾炎、肾移植及使用慢性糖皮质激素的患者更可能被处方耶氏肺孢子菌肺炎预防;使用移植诱导药物、钙调神经磷酸酶/mTOR抑制剂、环磷酰胺和霉酚酸酯的患者相比其他免疫抑制剂更可能被处方预防。
关键数值与推荐
- 977例系统性红斑狼疮患者中4例确诊耶氏肺孢子菌肺炎感染。
- 977例系统性红斑狼疮患者中132例(14%)被处方耶氏肺孢子菌肺炎预防。
- 617例曾处方免疫抑制剂的系统性红斑狼疮患者中128例(21%)被处方耶氏肺孢子菌肺炎预防。
- 磺胺类药物占预防处方的69%,117次磺胺暴露中22次记录可能不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective No guidelines exist for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE). Limited data are available on incidence of PJP infection and use of PJP prophylaxis. Using a real-world, electronic health record (EHR) cohort, we investigated the frequency of PJP infections as well as patient and provider factors that impacted use and type of PJP prophylaxis. Methods In a large, de-identified EHR, we identified possible SLE patients using a previously validated algorithm. PJP ICD-9 or ICD-10-CM billing codes and PJP keywords were used to identify possible PJP cases within this SLE cohort. We assessed for PJP prophylaxis prescribing in all SLE patients using keywords and reviewing medication lists for prophylactic agents. Chart review was used to confirm cases of SLE, PJP, and PJP prophylaxis and to obtain data on demographics, comorbidities, and immunosuppressants. Results Of 977 SLE patients, there were only four with confirmed PJP infection. Two of these patients had concurrent Acquired Immunodeficiency Syndrome, and none were on prophylaxis. Of 977 SLE patients, 132 (14%) were prescribed PJP prophylaxis. Of 617 SLE patients ever prescribed immunosuppressants, 128 (21%) were prescribed PJP prophylaxis. Sulfonamides were the most common prophylaxis prescribed (69%), and possible adverse events were documented in 22 out of 117 instances of being placed on a sulfonamide. Patients of younger age, Black race, nephritis, and renal transplant, and on chronic glucocorticoids were all more likely to have PJP prophylaxis prescribed. Patients who were on transplant induction medications, calcineurin/mTOR inhibitors, cyclophosphamide, and mycophenolate mofetil all were more likely to be prescribed PJP prophylaxis compared to other immunosuppressants. Conclusion PJP is a rare diagnosis among SLE patients, and prior studies may even overestimate its prevalence. PJP prophylaxis was less common in our cohort than previously described. Adverse events related to sulfonamides used for PJP prophylaxis were relatively rare with lower rates than previously reported. Our study demonstrates real-world PJP prophylaxis prescribing patterns in a large cohort of SLE patients.
引用
- Boone B, Lazaroff SM, Wheless L, et al. Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2022. PMID: 36279805. doi:10.1016/j.semarthrit.2022.152106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。